Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hepatocellular Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(222)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 3 weeks (New B)
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 3wk
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 3 weeks
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 3 weeks - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks (New B)
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 3wk
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 3 weeks - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
durvalumab + tremelimumab
Sensitive: A1 - Approval
durvalumab + tremelimumab
Sensitive
:
A1
durvalumab + tremelimumab
Sensitive: A1 - Approval
durvalumab + tremelimumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
NTRK3 fusion
Hepatocellular Cancer
NTRK3 fusion
Hepatocellular Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Hepatocellular Cancer
NTRK2 fusion
Hepatocellular Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Hepatocellular Cancer
NTRK1 fusion
Hepatocellular Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Hepatocellular Cancer
NTRK3 fusion
Hepatocellular Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Hepatocellular Cancer
NTRK2 fusion
Hepatocellular Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Hepatocellular Cancer
NTRK1 fusion
Hepatocellular Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sirolimus
Sensitive: A2 - Guideline
sirolimus
Sensitive
:
A2
sirolimus
Sensitive: A2 - Guideline
sirolimus
Sensitive
:
A2
MSI-H/dMMR
Hepatocellular Cancer
MSI-H/dMMR
Hepatocellular Cancer
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
RET fusion
Hepatocellular Cancer
RET fusion
Hepatocellular Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
FGF21-H
Hepatocellular Cancer
FGF21-H
Hepatocellular Cancer
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
SRF388
Sensitive: B - Late Trials
SRF388
Sensitive
:
B
SRF388
Sensitive: B - Late Trials
SRF388
Sensitive
:
B
HGF-H + VEGFA-H
Hepatocellular Cancer
HGF-H + VEGFA-H
Hepatocellular Cancer
erlotinib + sorafenib
Resistant: B - Late Trials
erlotinib + sorafenib
Resistant
:
B
erlotinib + sorafenib
Resistant: B - Late Trials
erlotinib + sorafenib
Resistant
:
B
VEGFA-H
Hepatocellular Cancer
VEGFA-H
Hepatocellular Cancer
lenvatinib
Resistant: B - Late Trials
lenvatinib
Resistant
:
B
lenvatinib
Resistant: B - Late Trials
lenvatinib
Resistant
:
B
HGF elevation
Hepatocellular Cancer
HGF elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
CXCL8 elevation
Hepatocellular Cancer
CXCL8 elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
MET elevation
Hepatocellular Cancer
MET elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
ANGPT2 elevation
Hepatocellular Cancer
ANGPT2 elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
cabozantinib tablet
Resistant: B - Late Trials
cabozantinib tablet
Resistant
:
B
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
atezolizumab + cabozantinib tablet
Sensitive: B - Late Trials
atezolizumab + cabozantinib tablet
Sensitive
:
B
atezolizumab + cabozantinib tablet
Sensitive: B - Late Trials
atezolizumab + cabozantinib tablet
Sensitive
:
B
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
TTI-101 oral
Sensitive: B - Late Trials
TTI-101 oral
Sensitive
:
B
TTI-101 oral
Sensitive: B - Late Trials
TTI-101 oral
Sensitive
:
B
FGFR2 fusion
Hepatocellular Cancer
FGFR2 fusion
Hepatocellular Cancer
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
infigratinib
Sensitive: C1 - Off-label
infigratinib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login